Small Cell Lung Cancer Pipeline Report 2023: Emerging Therapies and Key pharma players involved by DelveInsight | Ascentage Pharma, Merck, Roche, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline

February 27 10:35 2023
Small Cell Lung Cancer Pipeline Report 2023: Emerging Therapies and Key pharma players involved by DelveInsight | Ascentage Pharma, Merck, Roche, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline
Small Cell Lung Cancer Pipeline

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa.

 

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

 

Some of Small Cell Lung Cancer Companies are:

  • Ascentage Pharma
  • Merck & Co
  • AstraZeneca
  • Advenchen Laboratories
  • GlaxoSmithKline
  • Advanced Accelerator Applications
  • Trillium Therapeutics
  • Vernalis
  • Oncoceutics
  • NewBio Therapeutics
  • Wigen Biomedicine
  • Linton Pharm
  • Carrick Therapeutics
  • Xencor
  • Jiangsu HengRui Medicine
  • Aileron Therapeutics
  • Roche
  • Ipsen
  • Celgene
  • Lee’s Pharmaceutical Limited
  • AbbVie
  • G1 Therapeutics
  • Chipscreen Biosciences
  • Luye Pharma Group
  • Shanghai Henlius Biotech
  • CSPC ZhongQi Pharmaceutical Technology
  • Impact Therapeutics
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

 

DelveInsight’s Small Cell Lung Cancer report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Some of Small Cell Lung Cancer Therapies:

  • APG-1252
  • Pembrolizumab
  • Olaparib
  • Lucitanib
  • Dostarlimab
  • Lutetium-177 oxodotreotide
  • Ontorpacept
  • S 055746
  • ONC 201
  • NBT-558
  • WJ-05129
  • LP-003
  • Samuraciclib
  • XmAb18087
  • SHR3162
  • ALRN-6924
  • Irinotecan sucrosofate
  • CC-90011
  • Gimatecan
  • ABBV-011
  • G1T28
  • Chiauranib
  • LY01610
  • HLX10
  • PLM60
  • IMP4297
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

 

Current Small Cell Lung Cancer Treatment Scenario and Small Cell Lung Cancer Emerging Therapies:

  • How many companies are developing Small Cell Lung Cancer drugs?
  • How many Small Cell Lung Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Small Cell Lung Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Small Cell Lung Cancer: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Small Cell Lung Cancer Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Pembrolizumab: Merck & Co

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Dostarlimab: GlaxoSmithKline

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

AMG 757: Amgen

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

• Comparative Analysis

S 055746: Vernalis

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Small Cell Lung Cancer Key Companies

Small Cell Lung Cancer Key Products

Small Cell Lung Cancer- Unmet Needs

Small Cell Lung Cancer- Market Drivers and Barriers

Small Cell Lung Cancer- Future Perspectives and Conclusion

Small Cell Lung Cancer Analyst Views

Small Cell Lung Cancer Key Companies

Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting